Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
The University of Kansas, Kansas City, Kansas UT Southwestern Medical Center, Dallas, Texas